Progression-free survival

62% estimated 1-year PFS rate (95% CI: 45, 75)2

  • PFS was a secondary endpoint of the ZUMA-2 phase 2, single-arm, open-label study
  • PFS data are not included in the USPI. PFS data are descriptive and should be carefully interpreted in light of the single-arm design
Chart with probability of progression-free survival over time (months) Chart with probability of progression-free survival over time (months)

Pinch to zoom

CI=confidence interval; MCL=mantle cell lymphoma; NE=not estimable; PFS=progression-free survival; R/R=relapsed or refractory; USPI=US Prescribing Information.

References: 1. TECARTUS™ (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2020. 2. Data on file. Kite Pharma, Inc; 2020.